AHA: Strategies Compared for Treating Chronic Limb-Threatening Ischemia
TUESDAY, Nov. 8, 2022 (HealthDay News) -- For patients with chronic limb-threatening ischemia (CLTI), an initial strategy of surgical revascularization is better than endovascular therapy for those with a single segment of great saphenous vein that could be used for surgery, according to a study published online Nov. 7 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2022, held from Nov. 5 to 7 in Chicago.
Alik Farber, M.D., from the Boston University School of Medicine, and colleagues conducted a randomized trial involving 1,830 patients with CLTI and infrainguinal peripheral artery disease in two parallel cohort trials. Cohort 1 included patients with a single segment of great saphenous vein that could be used for surgery and cohort 2 included patients who needed an alternative bypass conduit. A composite of major adverse limb event or death from any cause was assessed as the primary outcome.
The researchers found that after a median follow-up of 2.7 years, a primary outcome event occurred in 42.6 and 57.4 percent of patients in the surgical and endovascular groups, respectively, in cohort 1 (hazard ratio, 0.68; 95 percent confidence interval, 0.59 to 0.79; P < 0.001). After a median follow-up of 1.6 years, a primary outcome event occurred in 42.8 and 47.7 percent of patients in the surgical and endovascular groups, respectively, in cohort 2 (hazard ratio, 0.79; 95 percent confidence interval, 0.58 to 1.06; P = 0.12).
"Our findings support complementary roles for these two treatment strategies and emphasize the need for preprocedural planning to assess patients and inform what treatment is selected," Farber said in a statement.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Panel Addresses Ezetimibe, PCSK9 Inhibitors for Reducing CV Events
THURSDAY, May 5, 2022 (HealthDay News) -- In a clinical practice guideline...
Major Injury Fall, Pressure Ulcer Hospitalizations Underreported
THURSDAY, June 1, 2023 (HealthDay News) -- There is widespread underreporting of...
More Than 2 Million COVID Home Test Kits Recalled Due to False Positive Results
THURSDAY, Nov. 11, 2021 (HealthDay News) -- A recall of Ellume at-home COVID-19...
El letal ‘fentanilo arcoíris’ parece caramelos, y podría seducir a los niños
JUEVES, 1 de septiembre de 2022 (HealthDay News) -- La Administración de Control...